{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["146(20)"],"submitter":["Al-Sawaf O"],"pubmed_abstract":["<h4>Abstract</h4>Venetoclax-obinutuzumab (Ven-Obi) is a standard first-line therapy for chronic lymphocytic leukemia (CLL). The impact of age, fitness, and dose reductions remains unclear. We analyzed patients treated with Ven-Obi in the CLL13 and CLL14 trials, excluding patients with TP53 aberrations. Fitness was assessed using the cumulative illness rating scale (CIRS, >6) and creatinine clearance (≤70 mL/min). Among 410 patients (median age, 67 years), 55.7% were unfit (median age, 72 years) and 44.3% were fit (median age, 58 years). Overall response rate (ORR) was 89.5% in unfit and 96.1% in fit patients. Rates of undetectable minimal residual disease (uMRD) at <10-4 were 80.3% in unfit and 85.1% in fit patients. Progression-free survival (PFS) at 3 years was 86.4% vs 87.5% (hazard rat"],"journal":["Blood"],"pagination":["2406-2416"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12824677"],"repository":["biostudies-literature"],"pubmed_title":["The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL."],"pmcid":["PMC12824677"],"pubmed_authors":["da Cunha-Bang C","Janssens A","Sivcheva L","Wendtner CM","Fink AM","Gregor M","Staber P","Levin MD","Hallek M","Strumberg D","Schneider C","Juliusson G","Thornton P","Loscertales J","Tadmor T","Giza A","von Tresckow J","Robrecht S","Al-Sawaf O","Kreuzer KA","Eichhorst B","Kilfoyle A","Lindstrom V","Furstenau M","Kater AP","Illmer T","Niemann C","Simon F","Fischer K","Ritgen M","Tausch E","Schwarer A","Stilgenbauer S","Weinkove R"],"additional_accession":[]},"is_claimable":false,"name":"The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.","description":"<h4>Abstract</h4>Venetoclax-obinutuzumab (Ven-Obi) is a standard first-line therapy for chronic lymphocytic leukemia (CLL). The impact of age, fitness, and dose reductions remains unclear. We analyzed patients treated with Ven-Obi in the CLL13 and CLL14 trials, excluding patients with TP53 aberrations. Fitness was assessed using the cumulative illness rating scale (CIRS, >6) and creatinine clearance (≤70 mL/min). Among 410 patients (median age, 67 years), 55.7% were unfit (median age, 72 years) and 44.3% were fit (median age, 58 years). Overall response rate (ORR) was 89.5% in unfit and 96.1% in fit patients. Rates of undetectable minimal residual disease (uMRD) at <10-4 were 80.3% in unfit and 85.1% in fit patients. Progression-free survival (PFS) at 3 years was 86.4% vs 87.5% (hazard rat","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov","modification":"2026-06-06T20:11:54.222Z","creation":"2026-06-04T03:14:28.367Z"},"accession":"S-EPMC12824677","cross_references":{"pubmed":["40864973"],"doi":["10.1182/blood.2025028899"]}}